A total of 817 human immunodeficiency virus-infected Ethiopians with CD4 <150 cells/mL underwent plasma cryptococcal antigen (CRAG) screening. CRAG prevalence was 6.2%. Of participants with plasma CRAG titers >1:640, 96% (27 of 28) had cryptococcal meningitis (cerebrospinal fluid CRAGpositive) whereas 50% (7 of 14) with 1:160-1:320 titers had meningitis. With fluconazole 1200 mg/d therapy, 68% of meningitis patients (23 of 34) died within 3 months. Plasma CRAG titers >1:160 predict meningitis, requiring more intensive antifungal therapy.
Cryptococcosis is a neglected killer in sub-Saharan Africa, causing 15% of AIDS-related deaths [1] . However, screening can detect early disseminated, subclinical infection, and giving preemptive antifungal treatment to a targeted cryptococcal antigen (CrAg)-positive population prevents death [2] [3] [4] [5] . Overall, CrAg screening is cost saving for health systems [6, 7] . The World Health Organization (WHO) recommends integrating CrAg screening among human immunodeficiency virus (HIV)-infected persons who are not receiving effective antiretroviral therapy (ART) and have CD4 + T-cell counts <100/µL [8] . This recommendation is included in 2016 WHO consolidated ART guidelines and HIV guidelines from 22 countries [8] .
The prevalence of asymptomatic cryptococcal antigenemia among HIV-infected persons with CD4 + T-cell counts <100/ µL averages 7%, with regional variation [1, 9] . For those who are asymptomatic but plasma CrAg positive, ART alone does not adequately treat cryptococcal antigenemia, and antifungal preemptive therapy is necessary [2, 3] . However, current preemptive therapy is based on expert opinion, and 25%-30% of CrAg-positive persons die after failure of preemptive therapy [2, 4] . We hypothesized that a plasma CrAg threshold could identify those with probable cerebrospinal fluid (CSF) CrAg positivity to enable customized, improved preemptive therapy.
METHODS
We performed an observational, prospective cohort study evaluating CrAg screening and preemptive treatment at Asella and Adama referral hospital HIV clinics from August 2014 to March 2016. We implemented laboratory-based reflex CrAg screening by lateral flow assay (Immy) at time of CD4 testing from the remaining plasma specimen among HIV-infected patients aged >14 years with CD4 + T-cell counts ≤150/µL (Supplementary Figure S1 ).
Institutional review board approvals were obtained from Arsi University College of Health Sciences and University of Minnesota. The screening program targeted patients who were ART naive or ART defaulters, that is, those previously receiving ART who had dropped out of HIV care for >3 months. Viral load monitoring was part of routine care. Plasma CrAg-positive participants provided written informed consent for lumbar punctures (LPs) and study participation. All CrAg-positive participants were offered LPs, and CrAg CSF was tested using lateral flow assay. CrAg titers were prospectively determined for both plasma and CSF.
For plasma-positive participants with negative CSF CrAg results, fluconazole was prescribed for 2 weeks 800 mg/d, followed by 400 mg/d for 8 weeks and then secondary prophylaxis with 200 mg/d. Those who were CSF positive were treated with fluconazole for 2 weeks at 1200 mg/d, because amphotericin is not routinely available, then fluconazole for 8 weeks at 800 mg/d, and then secondary prophylaxis. Therapeutic LPs were performed for symptomatic participants at physician discretion [10] . ART was initiated between 4 and 8 weeks. All plasma CrAg-positive participants were traced at 3 months to ascertain outcome.
Statistical analysis was primarily descriptive. The primary outcome was 3-month survival time assessed via Cox regression analysis (SPSS 24; IBM). Categorical variables were compared using Fisher exact test. Differences were considered statistically significant at P < .05. and who were either ART naive or defaulters. We found a CrAgpositive prevalence of 6.2% (51 of 817). The number needed to test, to identify 1 person who was CrAg positive, was 16.0. The median CD4 + T-cell count in the CrAg-positive group was 41/µL (interquartile range, 18/µL to 72/µL), and 49% (25 of 51 participants) were men. As displayed in Supplementary  Table S1 , 76% (39 of 51) were ART naive, 69% (35/51) had CD4 + T-cell counts ≤50/µL, and 88% (45 of 51) had CD4 + T-cell counts <100/µL. All plasma CrAg-positive participants were offered LPs. LPs were performed in 90% (46 of 51), of whom 67% (31 of 46) were CSF positive. Another 3 CrAg-positive participants had overt symptomatic meningitis but did not undergo LP. Thus, in total, 67% (34 of 51) were probably CSF CrAg positive. The strongest predictor of CSF positivity was the plasma CrAg titer (Figure 1 ). Among 10 persons with a plasma CrAg titer ≤1:80, none were CSF positive. Among 20 with CrAg titers from 1:160 to 1:640, 65% (13 of 20) were CSF positive, including 6 of 7 with a titer of 1:640 and 7 of 14 with a titer of 1:160 or 1:320. Among 21 participants with a CrAg titer ≥1:1280, all were CSF positive or had symptomatic meningitis (P < .001). Thus, of participants with a plasma CrAg titer ≥1:640, 97% (28 of 29) had central nervous system (CNS) involvement. Correlation between the plasma and CSF CrAg titers was modest (Spearman ρ = 0.44; P = .01; Supplementary Figure S2) . Clinical signs and symptoms of meningitis were present in 65% of participants (22 of 34) who were CSF CrAg positive and 12% (2 of 17) who were CSF CrAg negative. Among 19 plasma CrAg-positive participants without signs of meningitis, 37% (7 of 19) were CSF positive.
We assessed clinical outcomes through 3 months in routine care. The case mortality rate was 24% (4 of 17 patients) for asymptomatic cryptococcal antigenemia versus 68% (23 of Figures S3  and S4 ). Among 31 CSF CrAg-positive persons, the mortality rate was 94% (17 of 18) among those with CSF CrAg titers ≥1:1280 and 38% (5 of 13) among those with CSF titers ≤1:640 (P = .001). In a multivariable Cox regression model, CSF titers ≥1:1280 remained independently associated with mortality rate (hazard ratio, 9.6; 95% confidence interval, 2.1-43.7; P = .003) with adjustment for plasma CrAg titer, CD4 + T-cell count, age, sex, ART status, and WHO clinical stage. Thus, the efficacy of fluconazole at 1200 mg/d was particularly poor at high fungal burdens, as measured by CSF CrAg titers.
DISCUSSION
Despite expansion of ART, many HIV-infected persons still present late to care. We found 6.2% plasma CrAg positivity among 817 persons with CD4 + T-cell counts <150/µL over 18 months. When LPs were performed systematically, nearly all persons with plasma CrAg titers ≥1:640 had CrAg detected in their CSF. At titers of 1:160 or 1:320, 50% had detectable CSF CrAg. Among those with plasma titers ≤1:80, none had detectable CSF CrAg. Most guidelines recommend amphotericin B plus flucytosine for 2 weeks as the initial induction treatment for cryptococcal meningitis. However, the accessibility of these 2 medicines in Africa is limited where the disease burden is most prevalent. Thus, we used high-dose fluconazole monotherapy as induction therapy; however, persons with meningitis had a dramatically higher mortality rate-68% compared with 27% among those with isolated cryptococcal antigenemia who are CSF CrAg negative. Previous cryptococcal meningitis studies have demonstrated reduced survival with high-dose fluconazole monotherapy [11] . One option in resource-limited settings is to use short-course amphotericin B with combination of highdose fluconazole for cryptococcal meningitis, if available. The cold chain (4°C) necessary for amphotericin B deoxycholate storage makes it challenging, even if cost-effective [12] . In contrast, liposomal amphotericin B storage temperature is 25°C, and short-course trials are commencing in 2017.
In resource-limited settings, there are still barriers to appropriate management of AIDS-related opportunistic infections. Timely ART initiation, stock-outs of essential medicines (including antifungals), and competing priorities among a shortage of healthcare workers are some of the challenges. The absence of first-line drugs, such as amphotericin and flucytosine, is clearly a major contributors to the high cryptococcal case mortality rates.
Ethiopian national guidelines follow the WHO guidelines recommending high-dose fluconazole as first-line option A for cryptococcal meningitis. In our experience, this is not sufficient, with a mortality rate of 68% (95% confidence interval, 49%-83%). Our study highlights the high prevalence of CSF CrAg positivity among persons with AIDS. To our knowledge, the role of LPs has not been previously studied. Understandably, LPs are frequently declined in this asymptomatic population [13] ; however, we found 37% of asymptomatic persons with CrAg-positive plasma had CSF positivity, of whom all had plasma CrAg titers ≥1:160. Of those with plasma titers ≥1:640, 97% were CSF positive. Cases with CSF CrAg titers ≥1:1280 were almost universally fatal with fluconazole therapy.
The limitations of this study include the relatively small sample sizes of the subgroups, limiting the accuracy of any point estimate. The best clinical management of persons with asymptomatic antigenemia, especially those with high plasma CrAg titers, is unclear. In our opinion, those with plasma CrAg titers ≥1:160 should be assumed to have widely disseminated disease, including probable CNS involvement. Titers ≥1:640 should be viewed as emergent results with assumed definite CNS involvement, regardless of symptoms. Based on our results, the role for diagnostic LP in asymptomatic persons seems to be in a very narrow window among those with plasma CrAg titers 1:160 to 1:320. Below this level, persons are CSF CrAg negative, and above it almost all are CSF CrAg positive.
Further evaluation of the management of asymptomatic cryptococcal antigenemia is warranted. The original WHO recommendation for an initial 2 weeks of fluconazole at 800 mg/d confirmed was made when nevirapine was still being used, with concern for potentially harmful fluconazole-nevirapine interactions. Based on the timing of mortality rates, longer durations of higher-dose fluconazole (1200 mg/d) may have benefit for plasma CrAg titers ≤1:640. However, the approximately 60% mortality rate by 2 weeks among persons with plasma CrAg titers ≥1:1280 by suggests that short-course amphotericin-based therapy is necessary [14, 15] . Further trials are needed to define optimal management.
Laboratory-based reflex CrAg screening was successfully implemented prospectively at 2 Ethiopian regional hospitals. Plasma CrAg titers ≥1:160 were predictive of an increasing probability of CSF CrAg positivity. CrAg screening may also identify persons with early meningitis. Further studies are needed to prioritize improved preemptive therapy in persons with serum or plasma CrAg titers ≥1:160.
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